

Tbo-filgrastim Inpatient Formulary Interchange

P&T committee automatic interchange of tbo-filgrastim (Granix™) for filgrastim (Neupogen®) in adults experiencing or expected to experience neutropenia from myelosuppressive chemotherapy used to treat non-myeloid malignancies.

Restriction of filgrastim (Neupogen®) to use in hematopoietic (bone marrow) stem cell transplantation; myeloid malignancies; and in pediatric patients.

Interchange:

- Filgrastim 300 mcg subcutaneously to Tbo-filgrastim 300 mcg subcutaneously.
- Filgrastim 480 mcg subcutaneously to Tbo-filgrastim 480 mcg subcutaneously.

Restrictions:

1. Filgrastim will be restricted to use in stem cell mobilization prior to hematopoietic (bone marrow) stem cell transplantation and for colony stimulation post stem cell transplantation.
2. Filgrastim will also be restricted to use for colony stimulation in myeloid malignancies (acute myeloid leukemia [AML], chronic myeloid leukemia [CML], myelodysplastic syndrome [MDS])
3. Filgrastim will be restricted for use in pediatric patients.

Reason: Approved by P&T Committee and Oncology Service Line in July/August of 2014. Tbo-filgrastim is a granulocyte colony stimulating factor FDA approved for use with myelosuppressive chemotherapy to reduce the duration of severe neutropenia in patients with nonmyeloid malignancies. Interchange to tbo-filgrastim will be a substantial cost savings measure for the hospital system. Tbo-filgrastim will be restricted to inpatient use only.

OLOL CSF Inpatient Guide

Clinical Scenario	Granix (tbo-filgrastim)	Neupogen (filgrastim)	Neulasta (pegfilgrastim)	Comments
Neutropenia from myelosuppressive chemotherapy for non-myeloid malignancies	Preferred agent	Interchange to tbo-filgrastim at same dosing schedule	Do not use	<u>Examples of non-myeloid malignancies:</u> Solid tumors such as breast/colon cancers Acute lymphocytic leukemia (ALL) Lymphomas (Hodgkin's disease, NHL, etc.)
Patient with a myeloid malignancy	Do not use	Preferred agent	Do not use	<u>Examples of myeloid malignancies:</u> Acute myeloid leukemia (AML) Acute promyelocytic leukemia (APL) Chronic myeloid leukemia (CML) Myelodysplastic syndrome (MDS)
Mobilization before stem cell transplant	Do not use	Preferred agent	Do not use	<u>Example:</u> Given after high dose cyclophosphamide for multiple myeloma patients who will have stem cells collected
Post autologous stem cell transplantation	Do not use	Preferred agent	Acceptable alternative per P&T	<u>Example:</u> Patients in OSCU 5WA receiving high dose chemotherapy, receive their stem cells, then receive CSF
Pediatric patients	Do not use	Preferred agent	Do not use	< 18 years of age

Note: Neupogen (filgrastim) and Neulasta (pegfilgrastim) are both available for use in the outpatient setting.